Raymond James Financial
IPSC icon

Raymond James Financial’s Century Therapeutics IPSC Stock Holding History

Raymond James Financial’s Portfolio IPSC Stock Details IPSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$206K Hold
91,323
– – ﹤0.01% 4872
2025
Q4 		$90.8K Hold
91,323
– – ﹤0.01% 4945
2025
Q3 		$45.5K Hold
91,323
– – ﹤0.01% 4834
2025
Q2 		$51K Buy
+91,323
New +$49K ﹤0.01% 5174

Other funds holding IPSC

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Raymond James Financial's IPSC Position: Q1 2026 in Review

Raymond James Financial held its Century Therapeutics (IPSC) position steady in Q1 2026 at 91,323 shares worth $206K. The position accounts for ﹤0.01% of the portfolio, ranked #4872.

Raymond James Financial first reported a position in IPSC in Q2 2025 and has held it in 4 quarters since. 72 funds tracked by Wall St. Rank hold IPSC as of Q1 2026.

  • Raymond James Financial held 91,323 shares of Century Therapeutics worth $206K as of Q1 2026.
  • Raymond James Financial left its Century Therapeutics share count unchanged in Q1 2026.
  • Century Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #4872 holding.
  • Raymond James Financial first reported a position in Century Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 72 funds tracked by Wall St. Rank held Century Therapeutics as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.